Could AstraZeneca double your money despite vaccine woes?

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Why would someone want to invest in a company that seems to be constantly making headlines for all the wrong reasons? Between manufacturing snags, clinical trial inconsistencies, repeated hiccups with regulators on both sides of the Atlantic, and a global public clamoring for coronavirus vaccination, AstraZeneca‘s (NASDAQ: AZN) reputation is getting a beatdown, and its stock is struggling. What’s more, these issues have played out every few months over nearly a year’s time, making them much easier to integrate into a narrative of a mounting meltdown. 

As monumental as the company’s stumbles may seem, however, investors…